Sikander Ailawadhi, MD

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’'s study on “"Hematologists’' Approach to Discussing Older Patients’ Values in the Context of Allogeneic Hematopoietic Cell Transplantation”" explored the methodologies hematologists use to engage older patients in treatment decisions, highlighting key findings related to patient values and the importance of incorporating these factors into transplant decision-making for improved patient-centered care.

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world factors influencing treatment decisions, highlighting the significant role of survivorship burden and patient preferences, and emphasizing how these findings should shape the management strategies for patients with multiple myeloma.

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Prospective Patient Preference Study for BTKi Treatment Attributes in CLL and SLL” explored the factors influencing patient decision-making, revealing key treatment preferences and highlighting the importance of incorporating these insights into clinical practice when selecting BTK inhibitors for patients with CLL or SLL.

Sikander Ailawadhi, MD, discusses how emerging trends in targeted therapies, immunotherapies, and precision medicine presented at ASH 2024 are addressing unmet needs in the management of hematologic cancers and shaping future treatment strategies.